Amylyx Pharmaceuticals (AMLX) financial statements
Amylyx Pharmaceuticals reported revenue of $0 in fiscal 2025, up 574.3% a year over 3 years.
Net income was -$145M.
Free cash flow was -$123M.
The diluted share count rose 1336% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Amylyx Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $285,000 | $22M | $381M | $87M | $0 |
| Cost of revenue | — | $3M | $25M | $6M | $0 |
| Gross profit | — | $19M | $355M | $81M | $0 |
| Research and development | $44M | $93M | $128M | $104M | $90M |
| Selling, general and admin | $39M | $127M | $188M | $114M | $63M |
| Operating income | -$83M | -$201M | $39M | -$315M | -$153M |
| Pre-tax income | -$88M | -$198M | $54M | -$302M | -$145M |
| Income tax | — | $774,000 | $5M | -$393,000 | $46,000 |
| Net income | -$88M | -$198M | $49M | -$302M | -$145M |
| EPS (diluted) | -$13.35 | -$3.39 | $0.70 | -$4.43 | -$1.53 |
| Diluted shares | 7M | 58M | 70M | 68M | 95M |
| Gross margin | — | 86.5% | 93.3% | 93.2% | — |
| Operating margin | -29013.3% | -905.7% | 10.2% | -360.2% | — |
| Net margin | -30853.0% | -892.4% | 12.9% | -345.4% | — |
Balance sheet
Fiscal years, from Amylyx Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash and short-term investments | $96M | $347M | $371M | $177M | $317M |
| Receivables | — | $15M | $40M | $447,000 | $88,000 |
| Inventory | — | $10M | $38M | — | — |
| Total current assets | $105M | $382M | $465M | $189M | $324M |
| Property, plant and equipment | $474,000 | $3M | $3M | $961,000 | $310,000 |
| Total assets | $106M | $391M | $517M | $194M | $333M |
| Total current liabilities | $17M | $47M | $82M | $28M | $23M |
| Total liabilities | $17M | $51M | $84M | $29M | $27M |
| Shareholders' equity | -$151M | $341M | $433M | $165M | $305M |
| Net debt | -$50M | -$63M | -$170M | -$77M | -$227M |
Cash flow
Fiscal years, from Amylyx Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating cash flow | -$75M | -$180M | $12M | -$168M | -$123M |
| Capital spending | $353,000 | $3M | $1M | $157,000 | $138,000 |
| Free cash flow | -$75M | -$182M | $11M | -$168M | -$123M |
| Stock-based compensation | $3M | $22M | $37M | $33M | $28M |
| Free cash flow margin | -26369.1% | -820.5% | 2.8% | -192.1% | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for AMLX.
Open AMLX in InvestinglyQuestions
What was Amylyx Pharmaceuticals's revenue in 2025?
$0 in fiscal 2025, from its 10-K filing.
How much free cash flow does Amylyx Pharmaceuticals generate?
-$123M in fiscal 2025 (operating cash flow minus capital spending).
From Amylyx Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.